Literature DB >> 25516787

Biological and Structural Characterization of Rotamers of C-C Chemokine Receptor Type 5 (CCR5) Inhibitor GSK214096.

Wieslaw M Kazmierski1, Susan Danehower1, Maosheng Duan1, Robert G Ferris1, Vassil Elitzin1, Douglas Minick1, Matthew Sharp1, Eugene Stewart1, Manon Villeneuve1.   

Abstract

We recently reported the discovery of preclinical CCR5 inhibitor GSK214096, 1 (J. Med. Chem. 2011, 54, 756). Detailed characterization of 1 revealed that it exists as a mixture of four separable atropisomers A-D. The two slow-interconverting pairs of rotamers A + B and C + D were separated and further characterized. HIV and CCR5-mediated chemotaxis data strongly suggest that the antiviral potency of 1 is due to rotamers A + B and not C + D. Furthermore, integrated UV, vibrational circular dichroism VCD and computational approach allowed to determine the M chirality in C + D (and P chirality in A + B). These findings imply additional avenues to be pursued toward new CCR5 antagonists.

Entities:  

Keywords:  CCR5; GSK214096; HIV inhibitor; antagonist; atropisomer; chemokine; entry inhibitor

Year:  2014        PMID: 25516787      PMCID: PMC4265823          DOI: 10.1021/ml5004124

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  22 in total

1.  Absolute configuration determination of chiral molecules in the solution state using vibrational circular dichroism.

Authors:  Teresa B Freedman; Xiaolin Cao; Rina K Dukor; Laurence A Nafie
Journal:  Chirality       Date:  2003-11       Impact factor: 2.437

Review 2.  Chemokine blockers--therapeutics in the making?

Authors:  Timothy N C Wells; Christine A Power; Jeffrey P Shaw; Amanda E I Proudfoot
Journal:  Trends Pharmacol Sci       Date:  2005-11-28       Impact factor: 14.819

3.  Donor CCR5 Delta32 polymorphism and outcome following cardiac transplantation.

Authors:  J E Fildes; A H Walker; R Howlett; M N Bittar; I V Hutchinson; C T Leonard; N Yonan
Journal:  Transplant Proc       Date:  2005-06       Impact factor: 1.066

Review 4.  Assessing atropisomer axial chirality in drug discovery and development.

Authors:  Steven R Laplante; Lee D Fader; Keith R Fandrick; Daniel R Fandrick; Oliver Hucke; Ray Kemper; Stephen P F Miller; Paul J Edwards
Journal:  J Med Chem       Date:  2011-09-15       Impact factor: 7.446

5.  Revealing atropisomer axial chirality in drug discovery.

Authors:  Steven R LaPlante; Paul J Edwards; Lee D Fader; Araz Jakalian; Oliver Hucke
Journal:  ChemMedChem       Date:  2011-01-05       Impact factor: 3.466

Review 6.  Chemokine receptor CCR5: from AIDS to atherosclerosis.

Authors:  K L Jones; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 7.  Chemokine antagonists as therapeutics: focus on HIV-1.

Authors:  Athe M N Tsibris; Daniel R Kuritzkes
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

8.  The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.

Authors:  Enrique Gonzalez; Hemant Kulkarni; Hector Bolivar; Andrea Mangano; Racquel Sanchez; Gabriel Catano; Robert J Nibbs; Barry I Freedman; Marlon P Quinones; Michael J Bamshad; Krishna K Murthy; Brad H Rovin; William Bradley; Robert A Clark; Stephanie A Anderson; Robert J O'connell; Brian K Agan; Seema S Ahuja; Rosa Bologna; Luisa Sen; Matthew J Dolan; Sunil K Ahuja
Journal:  Science       Date:  2005-01-06       Impact factor: 47.728

Review 9.  Chemokines and cancer.

Authors:  Albert Zlotnik
Journal:  Int J Cancer       Date:  2006-11-01       Impact factor: 7.396

10.  Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1.

Authors:  Wieslaw M Kazmierski; Christopher Aquino; Brian A Chauder; Felix Deanda; Robert Ferris; Deborah K Jones-Hertzog; Terrence Kenakin; Cecilia S Koble; Christian Watson; Pat Wheelan; Hanbiao Yang; Michael Youngman
Journal:  J Med Chem       Date:  2008-09-24       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.